Immigration Office Streamlines Electronic Record Keeping
Published Date: 8/29/2025
Notice
Summary
The Executive Office for Immigration Review is updating its record system to include new electronic files and combine old records for easier management. This change affects anyone involved in immigration appeals and helps the office work smarter and faster. The update is happening now, with no extra costs to the public.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Immigration appeal records consolidated
If you are involved in an immigration appeal, the Executive Office for Immigration Review (EOIR) is changing its records system to add new electronic files and combine older records into a retitled system called "Adjudication and Appeal Records of the Office of the Chief Immigration Judge and Board of Immigration Appeals." EOIR also said it will adopt new and modified routine uses for the system, and that the change is happening now with no extra costs to the public.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-15458, Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority
This notice of proposed rulemaking ("NPRM") would implement a provision of the Immigration and Nationality Act ("INA" or "the Act") that authorizes Immigration Judges, under regulations prescribed by the Attorney General, to sanction by civil money penalty any action (or inaction) in contempt of the proper exercise of their authority by certain individuals. The rule would: define the scope of the contempt authority; provide procedures for contempt findings, penalty determinations, and penalty payment; establish an appellate process; and implement oversight of the use of contempt authority. The rule would also make conforming changes to the grounds for practitioner discipline.
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-09160, Implementing PATRIOT Act Improvements: Contraband Cigarettes and Smokeless Tobacco
Starting June 8, 2026, new rules crack down harder on illegal cigarette and smokeless tobacco sales. The government lowered the amount that counts as smuggling from 60,000 to just 10,000 cigarettes and now includes smokeless tobacco in the crackdown. Sellers and distributors must keep better records and report more info, making it tougher to dodge the law and protect honest businesses.
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
2026-16775, Notice of Lodging of Proposed Consent Decree Under the Clean Water Act
Previous / Next Documents
Previous: 2025-16640, Records Governing Off-the-Record Communications; Public Notice
The Federal Energy Regulatory Commission (FERC) is sharing updates about off-the-record communications—those secret chats that can’t directly affect decisions unless fairness calls for it. If you’re involved in a case, you might see summaries or copies of these talks, and you can ask to respond or have them included officially. This keeps things fair and transparent, with no new costs or deadlines for most folks.
Next: 2025-16646, Amylyx Pharmaceuticals, Inc.; Withdrawal of Approval of New Drug Application for RELYVRIO (Sodium Phenylbutyrate and Taurursodiol) for Suspension, 3 Gram/Packet and 1 Gram/Packet
Amylyx Pharmaceuticals asked the FDA to take back its approval for the drug RELYVRIO, used in 1g and 3g packets. This means RELYVRIO won’t be available as an FDA-approved treatment anymore. Patients and healthcare providers should watch for updates on how this change might affect treatment options and costs.